Sanofi (SNYN) — Free Cash Flow Generation Index

Latest as of March 2026: 1.00x

Sanofi (SNYN) has a Free Cash Flow Generation Index of 1.00x as of March 2026. Free cash flow of MX$1.68 Billion represents 1% of operating cash flow (MX$1.68 Billion). Read Sanofi debt and liabilities for a breakdown of total debt and financial obligations.

FCF Generation Index

1.00x
Free Cash Flow / Operating CF

Free Cash Flow

MX$1.68 Billion
MXN

Operating Cash Flow

MX$1.68 Billion
MXN

Capital Expenditures

MX$0.00
MXN

Sanofi Free Cash Flow Generation Index (2013–2025)

Historical FCF Generation Index trend for Sanofi across 13 annual periods. Explore SNYN capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.

Annual Free Cash Flow Generation for Sanofi (2013–2025)

Year-by-year Free Cash Flow Generation Index for Sanofi. For the full company profile including market capitalisation, see Sanofi market cap and net worth.

Year FCG Index Free Cash Flow (MXN) Operating CF Capital Expenditures YoY Change
2025 0.67x MX$7.21 Billion MX$10.75 Billion MX$3.54 Billion ▲ +3.5%
2024 0.65x MX$5.89 Billion MX$9.08 Billion MX$3.19 Billion ▼ -8.1%
2023 0.71x MX$7.23 Billion MX$10.26 Billion MX$3.02 Billion ▼ -10.8%
2022 0.79x MX$8.32 Billion MX$10.53 Billion MX$1.61 Billion ▼ -1.9%
2021 0.81x MX$8.48 Billion MX$10.52 Billion MX$1.48 Billion ▲ +12.0%
2020 0.72x MX$5.33 Billion MX$7.42 Billion MX$1.25 Billion ▼ -6.4%
2019 0.77x MX$5.93 Billion MX$7.71 Billion MX$1.32 Billion ▲ +19.4%
2018 0.64x MX$3.57 Billion MX$5.55 Billion MX$1.42 Billion ▼ -12.4%
2017 0.73x MX$5.42 Billion MX$7.38 Billion MX$1.39 Billion ▼ -41.9%
2016 1.27x MX$9.92 Billion MX$7.84 Billion MX$2.08 Billion ▲ +11.5%
2015 1.13x MX$10.12 Billion MX$8.92 Billion MX$1.20 Billion ▼ -4.5%
2014 1.19x MX$9.14 Billion MX$7.69 Billion MX$1.45 Billion ▲ +0.1%
2013 1.19x MX$8.26 Billion MX$6.95 Billion MX$1.31 Billion
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).